MiNK reports early Phase 2 data for agenT-797 in acute lung injury, Q2 2026 results
Initial patients in Ukraine trial showed Day 28 survival and improved oxygenation as MiNK also launched a paid named-patient access program in Brazil.
MiNK Therapeutics reported second quarter 2026 financial results on August 13, 2026, along with early observations from its randomized Phase 2 trial of agenT-797 in acute lung injury and ARDS. Randomized Phase 2 dosing initiated in May 2026, with MiNK beginning dosing at First Lviv Territorial Medical Union in Lviv, Ukraine, in collaboration with UNBROKEN Ukraine, within days of receiving Ministry of Health authorization.1 The trial, C-1300-02 (NCT07615010), is evaluating agenT-797 plus standard of care versus placebo plus standard of care in adults with acute lung injury and moderate-to-severe hypoxemic respiratory failure meeting Global ARDS Definition criteria1, and is being conducted under an active U.S. IND.1
Early results were presented at MHSRS. The initial agenT-797-treated patients were alive and afebrile at Day 28, with improved oxygenation and liberation from ventilator and vasopressor support, and microbiologic findings indicated control of baseline infections.1 Serum and bronchoalveolar lavage analyses showed reduced inflammatory markers and biologic changes associated with immune recovery, epithelial repair and pulmonary vascular recovery, and no major serious adverse events were attributed to agenT-797 in these initial patients.1 U.S. clinical center activation is underway while enrollment continues in Lviv, with additional data expected in early 2027.1
MiNK also disclosed a new access channel. The company is collaborating with Orphan Drug Consulting to support physician-initiated requests for agenT-797 for individually identified patients, expanding access for patients with serious unmet medical need while providing MiNK with program revenue, with each request subject to case-by-case Brazilian regulatory authorization.1 The program is not a commercial launch or marketing authorization.1
On finances, cash and cash equivalents were $8.8 million as of June 30, 2026, compared with $9.5 million as of March 31, 2026, and $13.4 million as of December 31, 2025.1 Net loss for the second quarter was $3.1 million, or $0.62 per share, versus $4.2 million, or $1.06 per share, a year earlier; for the six months ended June 30, 2026, net loss was $5.9 million, or $1.20 per share, versus $7.0 million, or $1.76 per share, in the same 2025 period.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.